Humana (HUM) Q3 2026 earnings review
Humana raises its profit outlook, but clinic costs jump
Humana, the US health insurer and clinic operator, lost less money than it planned this quarter while replacing a costly clinic buyout obligation. Revenue rose 26% from a year ago as Medicare Advantage and prescription drug membership expanded, and medical claims took 93.7% of insurance premiums against a forecast of slightly above 94%. Lower overhead costs helped chief executive Jim Rechtin lift the full-year profit floor, excluding one-offs, to at least $9.50 per share, though by our math that still leaves a fourth-quarter loss near $7.67 per share.
| Revenue | $41.2B +26% from a year ago |
|---|---|
| Insurance medical claims ratio | 93.7% beat plan of 'slightly above 94%' |
| Profit per share, excluding one-offs | ($0.70) beat plan of ~($1.00) |
| Full-year profit outlook, excluding one-offs | Raised $0.50 at least $9.50 per share |
⚖️ Verdict: 🟢 Bullish
The story got better because Humana removed a billion-dollar cash drain on its balance sheet and proved its medical cost assumptions are holding up. Replacing private-equity partner WCAS with BlackRock in its primary care clinics eliminated roughly $1.2 billion of buyout liabilities without adding a new put option. Two cautions temper the upgrade: operating profit at the CenterWell clinic unit fell 20% on higher patient care costs in one region, and management described its newly released 2028 quality bonus scores as approximating top quartile rather than confirming the specific revenue threshold it set last quarter.
The question now is whether the October quality ratings actually deliver the full bonus revenue Humana needs to reach a 3% pre-tax margin in 2028, or if clinic cost inflation and a smaller membership base will force deeper cuts. If the ratings cleared the bar, 2028 margin recovery stays on track; if they fell short, pricing and overhead must carry more weight. The December 10 investor update will provide the numbers.
🐂 Bull Case
BlackRock Deal Removes the Clinic Buyout Liability
Humana previously built new CenterWell senior primary care clinics through partnerships with private-equity firm Welsh, Carson, Anderson & Stowe (WCAS). Those agreements gave WCAS a put option, which is the right to force Humana to buy out the clinics for $1.0 billion to $1.5 billion in cash starting in 2027. That looming bill strained the health insurer's balance sheet during its profit trough.
In October, the Louisville-based group replaced the WCAS partnerships with a new joint venture with HPS Investment Partners, a unit of BlackRock. Humana stated that "The new JV does not include a put option exercisable by BlackRock" and means "we will no longer need to fund the puts associated with the former JVs, all else equal." Alongside a $900 million sale of its Gentiva stake closing in the fourth quarter, Humana reversed roughly $1.2 billion of net buyout liabilities on its September balance sheet and expects the BlackRock deal to trim its debt-to-capitalization ratio by another 1.3 percentage points in the fourth quarter.
What to watch: the exact size of the new derivative liability recorded on the fourth-quarter balance sheet. Management already projected a $2.14 per share non-cash charge for the initial option structure, and a small ongoing liability would confirm that the cash drain is gone.
Overhead Cuts Cushion Rising Medical Claims
"We are also increasingly driving financial and operating performance toward being 'ahead' of our plan," chief executive Jim Rechtin said. Because reduced government quality bonuses cut revenue this year, Humana relies on administrative cost cuts and disciplined pricing to limit its second-half losses.
In the third quarter, the Insurance unit spent 93.7% of its premiums on medical claims (its benefit ratio), beating its forecast of slightly above 94%. Medical and drug costs ran "in line to better than our expectations of ‘high single digit’ trend, across both new and existing membership", the company wrote. Meanwhile, company-wide overhead (the operating cost ratio) dropped 1.3 percentage points from a year ago to 11.3% of revenue, or 0.6 percentage points to 11.2% excluding one-offs, as centralising clinical review teams and lower restructuring charges paid off. That allowed Rechtin to lift the full-year profit floor, excluding one-offs, by $0.50 to at least $9.50 per share.
What to watch: whether management quantifies its realized 2026 cost savings at the December 10 investor update. Naming a dollar figure against its $1.6 billion to $2.0 billion 2028 target would show how much overhead relief remains for 2027.
Medicaid Expansion Adds Dual-Eligible Members
Humana is expanding its state-contracted Medicaid plans, especially for dual-eligible members who qualify for both Medicare and Medicaid. The insurer added 103,600 Medicaid members in the first nine months of 2026, a 7% gain driven by new dual-eligible launches in Michigan, Illinois and South Carolina. Total dual-eligible special needs plan membership reached 958,300, up 25% from a year ago. However, the company noted that "The states continue to navigate procurement challenges related to our recent awards in Texas and Georgia".
What to watch: the January 2027 launch of the statewide Illinois Medicaid contract and resolution of the Georgia and Texas procurement delays. Clearing those state hurdles would keep Medicaid adding members while Medicare Advantage shrinks next year.
🐻 Bear Case
Bonus Year 2028 Star Ratings Wording Shift
Medicare Advantage (MA) Star Ratings are annual government quality scores that determine billions of dollars in federal bonus payments two years later. Humana's entire plan to restore its pre-tax profit margin to at least 3% by 2028 depends on recovering the $3.5 billion of bonus revenue it lost for 2026. Bulls note that internal clinical metrics improved this year, and in October the federal government published the ratings that govern 2028 payments.
In its prepared remarks, the insurer declared itself "Proud of our industry leading Bonus Year 2028 MA Stars results" and said it will manage 2028 products and expenses "at a level that approximates Top Quartile results". Yet management gave no numbers from the October release. Last quarter, Humana defined top-quartile results as per-member bonus revenue at least 10% above the peer median. Saying it will manage expenses to approximate that level is not the same as confirming its actual scores cleared the 10% threshold.
What to watch: the exact Bonus Year 2028 Star Ratings revenue per member disclosed at the December 10 virtual investor update. Any result below the committed 10% premium to peers would force heavier benefit cuts or deeper overhead reductions to hit the 3% margin goal.
Primary Care Costs Jump Again at CenterWell
CenterWell is Humana's healthcare services arm, housing its senior primary care clinics, pharmacy and home health operations. While the Insurance unit sits near breakeven this year, CenterWell provides the group's operating profit. Bulls point to rapid scale: primary care patients grew 42.7% from a year ago to 637,900 across 399 clinics, and total segment revenue rose 21.7% to $7.16 billion.
- CenterWell operating cost ratio: 95.9% of revenue, up 2.0 percentage points from 93.9% a year ago
- Segment operating profit: $243 million (or $291 million excluding depreciation and amortization), down 20.3% from $305 million a year ago
- Primary care revenue per patient: about $1,121 per month by our math, down 3.8% from a year ago as newer clinics mix in
After a clean second quarter, clinic expenses flared up again. Humana blamed the final phase-in of federal risk-coding rules (v28) and higher primary care costs "primarily concentrated to a group of specific patients in a single geography, driven by patient and plan mix dynamics across multiple payor partners". By our math, hitting the middle of the full-year segment profit plan ($1.55 billion) requires $552 million of operating profit in the fourth quarter, almost double the third quarter's $243 million.
What to watch: fourth-quarter CenterWell operating profit against the $1.3 billion floor of the full-year plan. Falling short of that floor would show that clinic cost inflation and new-clinic losses are outweighing patient growth.
Drug Plan Growth Drives Steep Fourth-Quarter Loss
Humana has added 1.56 million members since December in stand-alone Medicare Part D prescription drug plans (PDP), bringing the total up 64.6% from a year ago to 4.03 million. About 350,000 of those additions came from employer group contracts separating drug coverage from medical plans, while the rest flocked to basic and value plans.
Under the Inflation Reduction Act, federal subsidies cover a larger share of drug costs, which lifted third-quarter PDP revenue 71.7% from a year ago to $3.01 billion. However, the law also shifts plan expenses heavily into the second half of the year, and pharmacy costs are rising faster than medical costs. Consequently, the Insurance unit lost $303 million in the third quarter and expects its fourth-quarter benefit ratio to reach just above 95.5%. By our math, the full-year breakeven outlook leaves an Insurance operating loss of $1.95 billion for the fourth quarter.
What to watch: fourth-quarter Insurance benefit ratio against the 95.5% target. A higher reading would indicate that drug utilization in the expanded Part D book is outrunning federal subsidies.
Risks this quarter didn't answer
Four standing concerns from prior quarters received no new quantitative data in the third-quarter materials because their catalysts fall during the winter enrollment period or in court.
- 2027 plan exits and member retention: Humana plans to exit unprofitable plans affecting roughly 600,000 Medicare Advantage members in 2027 to prioritize margin over growth; the December 10 update will give the first retention read.
- 2027 Medicare funding gap: management previously warned that the gap between federal rate increases and medical cost inflation widens in 2027; 2027 bid details in December will show how much benefit reduction was required.
- Federal risk-adjustment audits (RADV): the government's appeal of a court ruling striking down retroactive audit clawbacks remains pending at the Fifth Circuit.
- Broker payment and shareholder lawsuits: Justice Department intervention in a whistleblower suit over broker commissions and shareholder suits over 2022–2024 disclosures remain unresolved.
💲 Other KPIs
Total revenue rose 26.1% from a year ago, matching the second quarter's 26.2% pace and up from 23.5% in the first quarter. Higher Medicare Advantage and prescription drug plan membership, alongside increased federal Part D subsidies, drove the gain despite the 2026 Star Ratings bonus cut.
Nine-month operating cash flow more than doubled from $2,573 million a year ago, generating $2,163 million in the third quarter alone by our math. Medical claims payable (money owed for care already provided) rose 31.7% since December to $13.13 billion as membership grew, while days in claims payable held steady at 33.2 days.
Leverage dropped 1.8 percentage points from 42.7% in June and 2.1 percentage points from 43.0% in March. The insurer repaid short-term commercial paper during the quarter, cutting short-term debt from $2,268 million in June to $949 million in September.
🔮 Guidance
Raised. Management lifted its full-year floor by $0.50 after holding it at $9.00 for three quarters, which still leaves profit down at least 44.6% from $17.14 in 2025 due to lost Star Ratings bonuses. With $17.17 earned in the first nine months, the floor implies a fourth-quarter loss of up to $7.67 per share by our math, compared with a $3.96 loss a year ago.
Raised. After cutting the GAAP floor twice earlier this year (by $0.53 in the first quarter and $1.84 in the second), the company raised it by $8.57. The jump reflects an $11.42 per share non-cash accounting gain from cancelling the WCAS clinic buyout liability, partly offset by a $2.14 per share initial liability for the new BlackRock partnership. By our math, that leaves a fourth-quarter GAAP loss of $1.75 per share.
Unchanged. The plan still calls for at least 23.4% full-year revenue growth. With $121.67 billion booked in the first nine months, clearing the floor requires only $38.33 billion in the fourth quarter by our math, or 17.9% growth from a year ago versus 26.1% in the third quarter.
Unchanged. The floor represents at least 24.4% growth over 2025. After generating $116.28 billion through September, the unit needs $38.72 billion in the fourth quarter by our math, roughly matching the third quarter's $39.08 billion.
Unchanged. The target represents at least 11.2% growth for the year. With $20.05 billion recorded through the first three quarters, the floor leaves just $4.95 billion for the fourth quarter by our math, well below the third quarter's $7.16 billion run rate.
Unchanged. A 25% increase over the 5.25 million members at the end of 2025 points to about 6.56 million members by year-end. Enrollment stood at 6.46 million on September 30, up 23.0% year to date, leaving roughly 105,000 additions needed in the fourth quarter.
Unchanged. Group Medicare Advantage membership reached 728,300 at the end of September, already up 159,900 members from December 2025 and slightly ahead of the full-year target.
Unchanged. Management kept the 1 million target even though stand-alone drug plan membership has already grown by 1,564,900 since December to 4.03 million, aided by 350,000 group members whose drug coverage was separated from their medical plans.
Unchanged. In prepared remarks management noted year-to-date Medicaid growth of 103,600 members, while the statistical table shows total state-based contracts and other at 1,614,100 following the sunset of dual-eligible demonstration programs at the end of 2025.
Unchanged. Alongside the full-year band of 92.5% to 93.0%, management issued a fourth-quarter Insurance benefit ratio outlook of just above 95.5%. With the nine-month ratio at 91.4%, a 95.6% fourth quarter lands the full year at roughly 92.5% by our math.
Unchanged. Overhead excluding depreciation and amortization ran at 10.4% of revenue over the first nine months. Hitting the 10.0% full-year midpoint implies a drop to roughly 8.8% in the fourth quarter by our math, which is unusual because fourth-quarter enrollment marketing normally raises expenses.
Unchanged. The Insurance unit earned $1,952 million of GAAP operating profit in the first nine months, despite a $303 million third-quarter loss. A breakeven full year implies a $1,952 million operating loss in the fourth quarter by our math, driven by the Star Ratings bonus cut and seasonal drug claims.
Unchanged. CenterWell earned $998 million on a GAAP basis ($1,143 million excluding depreciation and amortization) in the first nine months. By our math, reaching the $1.55 billion GAAP midpoint requires $552 million in the fourth quarter, while the $1.3 billion floor requires $302 million.
Unchanged. The nine-month GAAP effective tax rate ran at 24.4% ($673 million tax provision on $2,763 million of pretax income), slightly below the full-year projection.
Unchanged. Diluted shares averaged 121.8 million in the third quarter and 121.2 million over the first nine months, as buybacks remained limited to offsetting employee stock compensation.
Unchanged. Nine-month operating cash flow of $5,383 million already sits $2.48 billion above the top of the full-year range. Hitting the $2.7 billion midpoint implies a $2.68 billion fourth-quarter cash outflow by our math as seasonal medical and drug claims are paid.
Unchanged. Net purchases of property and equipment totaled $390 million through September ($137 million in the third quarter by our math), leaving about $260 million of capital spending for the fourth quarter.
❓ Key Questions
Did Bonus Year 2028 Star Ratings clear the 10% peer-median bar?
Management called its October 2028 Star Ratings industry leading, but said it will manage 2028 expenses to approximate top-quartile results. Investors need the exact per-member bonus revenue relative to the peer median to know if the 3% margin bridge holds.
What caused the single-market primary care cost spike at CenterWell?
CenterWell's operating cost ratio jumped 2.0 percentage points to 95.9%, cutting segment operating profit by 20%. Management blamed patient and plan mix across outside insurers in one geography, but did not size the dollar drag or name the market.
What are the cash and financing terms of the BlackRock joint venture?
Replacing the WCAS clinic partnerships with BlackRock eliminated a $1.2 billion buyout liability, but created a $2.14 per share initial option liability and an ongoing derivative. Management has not disclosed BlackRock's return hurdle or how buyouts work if BlackRock exits.
How much of the 2028 cost-savings target is realized in 2026?
The company's overhead ratio fell 1.3 percentage points in the third quarter on clinical centralization and outsourcing. However, management has still not disclosed the total expected cost of its value creation program or the exact dollar savings booked this year.